Cognition Therapeutics (CGTX) Projected to Announce Earnings on Thursday

Cognition Therapeutics (NASDAQ:CGTX) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.06) per share and revenue of $5.00 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Cognition Therapeutics (NASDAQ:CGTX) last posted its earnings results on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. On average, analysts expect Cognition Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Cognition Therapeutics Price Performance

NASDAQ CGTX opened at $0.99 on Wednesday. The business’s fifty day moving average price is $1.14 and its 200-day moving average price is $1.13. The stock has a market capitalization of $88.61 million, a price-to-earnings ratio of -4.12 and a beta of 1.77. Cognition Therapeutics has a 1-year low of $0.55 and a 1-year high of $3.83.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of Cognition Therapeutics by 105.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,681,613 shares of the company’s stock worth $3,620,000 after purchasing an additional 1,377,263 shares in the last quarter. Acadian Asset Management LLC lifted its position in Cognition Therapeutics by 814.1% during the first quarter. Acadian Asset Management LLC now owns 1,007,586 shares of the company’s stock valued at $422,000 after purchasing an additional 897,353 shares in the last quarter. Renaissance Technologies LLC lifted its position in Cognition Therapeutics by 35.9% during the fourth quarter. Renaissance Technologies LLC now owns 969,513 shares of the company’s stock valued at $1,309,000 after purchasing an additional 256,013 shares in the last quarter. Geode Capital Management LLC lifted its position in Cognition Therapeutics by 22.6% during the fourth quarter. Geode Capital Management LLC now owns 873,954 shares of the company’s stock valued at $1,180,000 after purchasing an additional 161,227 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in Cognition Therapeutics during the third quarter valued at about $757,000. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Cognition Therapeutics in a research report on Monday, June 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Cognition Therapeutics in a research report on Wednesday, June 24th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Cognition Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $3.33.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.